COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) have earned a consensus rating of “Moderate Buy” from the nine ratings firms that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and seven have assigned a buy recommendation to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $15.8750.

Several analysts have commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of COMPASS Pathways in a research report on Wednesday, October 8th. BTIG Research upped their price objective on shares of COMPASS Pathways from $7.00 to $14.00 and gave the stock a “buy” rating in a report on Monday, October 13th. Finally, Morgan Stanley raised their target price on COMPASS Pathways from $10.00 to $11.00 and gave the company an “overweight” rating in a report on Wednesday, November 5th.

Institutional Investors Weigh In On COMPASS Pathways

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Nantahala Capital Management LLC grew its holdings in COMPASS Pathways by 182.9% during the first quarter. Nantahala Capital Management LLC now owns 2,829,232 shares of the company’s stock valued at $8,092,000 after purchasing an additional 1,829,232 shares during the last quarter. Vivo Capital LLC grew its stake in COMPASS Pathways by 109.1% in the 1st quarter. Vivo Capital LLC now owns 3,362,385 shares of the company’s stock valued at $9,616,000 after buying an additional 1,754,385 shares during the last quarter. Jefferies Financial Group Inc. acquired a new position in COMPASS Pathways in the 3rd quarter valued at $7,890,000. Woodline Partners LP raised its holdings in COMPASS Pathways by 279.9% in the 1st quarter. Woodline Partners LP now owns 1,754,856 shares of the company’s stock worth $5,019,000 after acquiring an additional 1,292,927 shares during the period. Finally, Ameriprise Financial Inc. acquired a new position in COMPASS Pathways during the 3rd quarter worth $6,926,000. 46.19% of the stock is currently owned by institutional investors and hedge funds.

COMPASS Pathways Stock Performance

Shares of CMPS stock opened at $5.68 on Friday. COMPASS Pathways has a fifty-two week low of $2.25 and a fifty-two week high of $7.09. The stock’s 50-day moving average is $5.90 and its two-hundred day moving average is $4.87. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.23 and a quick ratio of 1.23. The firm has a market cap of $545.39 million, a P/E ratio of -2.09 and a beta of 1.93.

COMPASS Pathways (NASDAQ:CMPS) last announced its quarterly earnings results on Tuesday, November 4th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.02. Analysts predict that COMPASS Pathways will post -2.33 earnings per share for the current fiscal year.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.